Cost-control programs boost OEC earnings
OEC Medical Systems reported a strong increase in net income forits 1995 fiscal year (end-December), although revenues were uponly slightly compared with 1994. OEC, of Salt Lake City, attributedthe earnings growth to improved profit margins that resulted
OEC Medical Systems reported a strong increase in net income forits 1995 fiscal year (end-December), although revenues were uponly slightly compared with 1994. OEC, of Salt Lake City, attributedthe earnings growth to improved profit margins that resulted fromcost-control programs.
For the year, OEC had revenues of $101.5 million, up 3% comparedwith $98.2 million in sales the year before. The company saidinternational sales were a bright spot, as it saw a 125% increasein revenues. In the U.S., however, the ongoing consolidation ofthe healthcare industry hurt sales. Orders in 1995 were levelwith those of 1994, but higher discounting resulted in lower revenues,according to OEC chief executive Ruediger Naumann-Etienne.
Net income for the year increased sharply. OEC registered earningsof $11.8 million, up 36% over the $8.7 million reported in theyear before. Naumann-Etienne said operating profit increased asthe company focused on improving manufacturing efficiencies andon controlling costs.
For the fourth quarter of 1995, OEC had net income of $3.4million on sales of $27.1 million, compared with net income of$3.1 million and sales of $28.2 million in the fourth quarterof 1994.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
